SQI Diagnostics (SQI Diagnostics) Growth Rank : 0 (As of Jun. 20, 2024)

View and export this data going back to 2009. Start your Free Trial

What is SQI Diagnostics Growth Rank?

SQI Diagnostics has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

SQI Diagnostics Growth Rank Related Terms

Thank you for viewing the detailed overview of SQI Diagnostics's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

SQI Diagnostics (SQI Diagnostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » SQI Diagnostics Inc (OTCPK:SQIDF) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

36 Meteor Drive, Toronto, ON, CAN, M9W 1A4

Website

https://www.sqidiagnostics.com

SQI Diagnostics Inc is the leader in the field of lung health. The company develops and manufactures respiratory health and precision medicine tests that run on SQI's automated systems. The company is developing tests to simplify and improve COVID-19 antibody monitoring, rapid acute lung injury testing, donor organ transplant informatics, and immunological protein and antibody testing. Its geographical segments are the United States, Canada, and Europe. Canada accounts for more than half of its revenues.